Assistant Clinical Professor, Division of Hematology/Oncology, UCSF
| CONTACT | |
|
(415) 353-9888 (appts) Box 1705, UCSF; San Francisco, CA 94143-1705 |
additional websites: |
| EDUCATION | |
|
Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
|
|
| PROFESSIONAL EXPERIENCE | |
|
1995-1996 |
Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine |
|
1996-1998 |
Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine |
|
1998-2001 |
Stanford University School of Medicine, fellow, Division of Medical Oncology |
|
2001-present |
University of California at San Francisco, Clinical Instructor, Division of Hematology/Oncology |
|
2003-present |
University of California at San Francisco, Assistant Clinical Professor, Division of Hematology/Oncology |
| HONORS & AWARDS | |
|
1987 |
National Merit Scholarship |
|
1988 |
IBM Thomas J. Watson Memorial Scholarship |
|
1990 |
Sigma Xi, elected associate member |
|
1991 |
Departmental honors and Magna cum laude, Brown University |
|
1993 |
Alpha Omega Alpha, student essay competition honoree |
|
1994 |
Harry C. Saltzstein Prize in Medical Writing, Johns Hopkins School of Medicine |
|
1995 |
Medical Assistance Programs/Reader's Digest International Fellowship |
|
2000 |
Amgen National Oncology Fellows' Forum, selected for oral presentation |
|
2000 |
American Society of Clinical Oncology, Travel Award (meritorious abstract) |
|
2001 |
Digestive Disease Center Collaborative Postdoctoral Fellowship |
|
2003 |
UCSF Cancer Center Clinical Investigator Research Program award |
|
2003 |
American Society of Clinical Oncology Career Development Award |
| SELECTED PUBLICATIONS | |
|
Original articles
| |
|
Ko, AH. Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China. Pharos 57(2): 11-15, Spring 1994. | |
|
Ko, AH, Thomas, DH, and Gallant, JH. Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor. AIDS 9(10): 1195-97, Oct 1995. | |
|
Lee, SR, Ramos, SM, Ko, A, Masiello, D, Swanson, KD, Lu, ML, and Balk SP. AR and ER Interaction with a p21-Activated Kinase (PAK6). Mol Endocrinol 16(1):85-99, Jan 2002. | |
|
Ko, AH, and Yuen, AR. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma 43(9):1789-93, Sept 2002. | |
|
Ko, AH, Bergsland, EK, and Lee, GA. Tumor associated hypoglycemia from metastatic colorectal adenocarcinoma. Dig Dis Sci 48(1):192-196, Jan 2003. | |
|
Ko, AH, Hwang, J, Venook, AP, Abbruzzese, J, Bergsland, EK, and Tempero, MA. Serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. Brit J Cancer 93(2):195-9, Jul 2005. | |
|
Ko, AH, Dito, E, Schillinger, B, Venook, AP, Bergsland, EK, and Tempero, MA. A phase II study of gemcitabine given at fixed-dose rate infusion in combination with low-dose cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol, 24(3): 379-85, Jan 2006. | |
|
Book chapters
| |
|
O'Neil B, Ko, AH, Rosenbaum, EH, Dollinger, M, and Mulvihill SJ, Stomach. In: Dollinger M, Rosenbaum EH, Tempero M, and Mulvihill SJ, eds. Everyone's Guide to Cancer Therapy. 4th ed. New York: Andrews McMeel Publishing, 2002. | |
|
O'Neil B, Ko, AH, Rosenbaum, EH, and Mulvihill SJ Small intestine. In: Dollinger M, Rosenbaum EH, Tempero M, and Mulvihill SJ, eds. Everyone's Guide to Cancer Therapy. 4th ed. New York: Andrews McMeel Publishing, 2002. | |
|
Ko, AH and Tempero, MA. Monoclonal antibodies and other targeted therapies. In: Von Hoff DD, Evans DB, and Hruban RH, eds. Pancreatic Cancer. Boston: Jones and Bartlett, 2005. | |
|
Review articles
| |
|
Gallant, JH, and Ko, AH. Cavitary pulmonary lesions in patients with human immunodeficiency virus. Clin Infect Dis 22: 671-82, 22 April 1996. | |
|
Ko, AH, and Tempero, MA. Current and future strategies for combined modality therapy in pancreatic cancer. Curr Onc Rep 4(4):202-212, May 2002. | |
|
Ko, AH, and Tempero, MA. The treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw., 3(5):627-36, Sep 2005. | |
|
Ko, AH, and Tempero, MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol, 15(4):245-53, Oct 2005. | |
|
Other publications
| |
|
Ko, AH. Adjuvant therapy for pancreatic cancer: is a combined-modality approach the optimal strategy? Abstr Hematol Oncol 5(3): 5-6, summer 2002. | |
|
Ko, AH, and Tempero, MA. Pancreatic cancer: new combinations and new agents. In: Medscape from WebMD (http://www.medscape.com), 2002. | |
|
Ko, AH. Study addressing potential role of preoperative radiotherapy in resectable gastric adenocarcinoma incomplete, outdated, but encourages further study. Abstr Hematol Oncol 6(1):6-7, winter 2003. | |
|
Ko, AH. Cancer of the pancreas, Cancer of the stomach. In: Cancer Supportive Care (http://www.cancer supportivecare.com), 2003. | |
|
Ko, AH and Venook, AP. Review of neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease. Clin Adv Hem Onc 1(12):743. | |
|
Ko, AH. Editorial, Though findings may be plausible, gaps and questions in study design blunt findings on the impact of adjuvant therapy for resected pancreatic cancer. Abstr Hematol Oncol, 7(2):6-8, spring 2004. | |
|
Selected abstracts/presentations
| |
|
Ko, AH and Yuen, AR. Poor prognosis associated with late relapse intermediate-grade non-Hodgkin's lymphoma. Proceedings of ASCO 57:17a, 2000. | |
|
Ko, AH and Kim, SK. Wnt signaling in pancreatic development, function, and disease. Presented at National Cancer Institute/Vanderbilt Symposium on Mouse Models of Pancreatic Cancer, Nashville, TN, May 2001. | |
|
Ko, AH, Renshaw, FG, Hwang, J, Lu, Y, Abbruzzese, J, Brand, R, and Tempero, MA. The prognostic value of CA19-9 in patients with advanced pancreatic cancer receiving fixed-dose rate gemcitabine. Proceedings of ASCO 259:1039, 2003. | |
|
Ko, AH, Dito, E, Schillinger, B, Venook, AP, Bergsland, E, and Tempero, MA. A phase II study of gemcitabine given at fixed-dose rate infusion in combination with cisplatin for metastatic adenocarcinoma of the pancreas. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, Jan 2004; Proceedings of ASCO 339:4107, 2004. | |
|
Ko, AH, Scott, J, Tempero, M, Venook, A, Bergsland, E, Park, J. Detection of circulating micrometastases by flow cytometry in patients with pancreatic carcinoma. Pancreatic Cancer 2004: Advances and Challenges, sponsored by AACR-Lustgarten Foundation, San Francisco, CA, Jun 2004. | |
|
Ko, AH, Dito, E, Schillinger, B, Hajnal, R, Venook, AP, Bergsland, EK, Allen, J, Rajpal, S, Wong, D, and Tempero, MA. A phase II study of gemcitabine given at fixed-dose rate infusion, low-dose cisplatin, and bevacizumab for metastatic adenocarcinoma of the pancreas. Proceedings of ASCO 188s:4041, 2006. |
|
|
12/6/06 |
|